Usefulness of monitoring linezolid trough serum concentration in prolonged treatments;Utilidad de monitorizar la concentración sérica en el valle de linezolid en pacientes que reciben tratamientos prolongados

Revista Espanola de Quimioterapia

Volumn 24, Issue 3, 2011, Pages 151-153

  Sousa, Ricardo ^a   López, Rosa ^b   Martínez Pastor, Juan C ^b   Cervera, Carlos ^b   Bori, Guillem ^b   García Ramiro, Sebastián ^b   Mensa, Josep ^b   Soriano, Alex ^b  

^a HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Linezolid; Musculoskeletal infections; Therapeutic drug monitoring

Indexed keywords

CIPROFLOXACIN; LINEZOLID; RIFAMPICIN;

ADULT; AGED; ANEMIA; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; STAPHYLOCOCCUS INFECTION; THROMBOCYTOPENIA;

ACETAMIDES; ADULT; AGED; ANTI-BACTERIAL AGENTS; DRUG MONITORING; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; GRAM-POSITIVE COCCI; HUMANS; MALE; MIDDLE AGED; MUSCULOSKELETAL DISEASES; ORTHOPEDIC PROCEDURES; OXAZOLIDINONES; PROSTHESIS-RELATED INFECTIONS; TREATMENT OUTCOME;

EID: 80054786923     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Livermore DM. Linezolid in vitro: mechanism and antibacterial spectrum. J Antimicrob Chemother 2003; 51 Suppl 2: 9-16.
2. Rana B, Butcher I, Grigoris P, Murnaghan C, Seaton RA, Tobin CM. Linezolid penetration into osteo-articular tissues. J Antimicrob Chemother 2002; 50: 747-50.
3. Soriano A, Gomez J, Gomez L, Azanza R, Perez R, Romero F. et al. Efficacy and tolerability of prolonged linezolid therapy in the treatment of orthopedic implant infections. Eur J Clin Microbiol Infect Dis 2007; 26: 353-6.
4. Papadopoulos A, Plachouras D, Giannitsioti E, Poulakou G, Giamarellou H, Kanellakopoulou K. Efficacy and tolerability of linezolid in chronic osteomyelitis and prosthetic joint infections: a casecontrol study. J Chemother 2009; 21: 165-9.
5. Soriano A, Miro O, Mensa J. Mitochondrial toxicity associated with linezolid. N Engl J Med 2005; 353: 2305-6.
6. Falagas ME, Siempos, II, Papagelopoulos PJ, Vardakas KZ. Linezolid for the treatment of adults with bone and joint infections. Int J Antimicrob Agents 2007; 29: 233-9.
7. Bressler AM, Zimmer SM, Gilmore JL, Somani J. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 2004; 4: 528-31.
8. Pea F, Scudeller L, Lugano M, Baccarani U, Pavan F, Tavio Met al. Hyperlactacidemia potentially due to linezolid overexposure in a liver transplant recipient. Clin Infect Dis 2006; 42: 434-5.
9. Garrabou G, Soriano A, Lopez S, Guallar J, Giralt M, Villarroya F, et al. Reversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemia. Antimicrob Agents Chemother 2007; 51: 962-7.
10. Soriano A, Ortega M, Garcia S, Peñarroja G, Bove A, Marcos M, et al. Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid. Antimicrob Agents Chemother 2007; 51: 2559-63.
11. Gandelman K, Zhu T, Fahmi OA, Glue P, Lian K, Obach R, et al. Unexpected Effect of Rifampin on the Pharmacokinetics of Linezolid: In Silico and In Vitro Approaches to Explain Its Mechanism. Journal Clin Pharmacol 2011; 51: 229-36.
12. Swoboda S, Ober MC, Lichtenstern C, Saleh S, Schwenger V, Sonntag H, et al. Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur J Clin Pharmacol 2010; 66: 291-8.